NeoStem Inc. is an international biopharmaceutical company. The company operates in three segments: Cell therapy (United States), regenerative medicine (China) and pharmaceutical manufacturing (China). NeoStem is a provider of adult stem cell collection, processing and storage services in the United States, enabling healthy individuals to donate and store their stem cells for personal, therapeutic use. In addition, the company collects and stores cord blood cells of newborns, which helps to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment. In January 2011, NeoStem completed the merger with Progenitor Cell Therapy LLC. In October 2011, the company acquired Amorcyte Inc.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
The Life Sciences Report Interview with Steve Brozak
"NeoStem Inc. sent out a shareholder letter on March 19 saying that it had crossed the 50% enrollment mark on its PreSERVE-AMI phase 2 clinical trial with AMR-001 (autologous, bone marrow-derived, CD34+ enriched cells) in ST-segment elevation acute myocardial infarction (STEMI; heart attack). There are more than 90 patients in the trial now, and that is more than satisfactory. The cells are drawn from the patient's bone marrow, and then enriched for CD34+ cells, which are known for vascularizing potency. The cells have a three-day shelf life from completion of processing. They are then reinjected into the affected areas of the myocardium via the coronary artery associated with the ischemia (loss of blood flow). This takes place a week or more after a stent placement procedure. Safety looks good, and enrollment should be completed this year, with a six- to eight-month time lag for readout after the final patient is treated. You have a much better outcome for patients who are treated with CD34+ cells, which allow restoration of blood supply to the affected areas."
NeoStem Inc. Content
Back to Top